Novel Embolizing Therapy for the Ablation of Solid Tumors

A common issue in the treatment of cancer is the unregulated toxic effects many therapies elicit on healthy tissues, without fully destroying the entire tumor. In addition, while studies show effective cell death with nanoparticle-based technologies, these particles frequently leech out of the target site into unintended regions of the body. This is due to the lack of a developed fixing agent to maintain nanoparticles locally in the tissue. This technology is the first to combine nanoparticles, radiofrequency, and embolization to destroy cancerous tissue and treat vascular-related disorders in a highly specific manner.

Researchers at Wake Forest have developed a technology that combines a nanoparticle-embedded embolizing agent with radiofrequency-stimulated thermal ablation to destroy vascularized tumors or unhealthy tissues.

Benefits of Novel Embolizing Therapy

  • Guided localization of the emboli-nanoparticle agent endovascularly ensures specific radiofrequency-induced tissue destruction without affecting the surrounding healthy tissue.
  • Unlike other nanoparticle therapies, the nanoparticles utilized in this technology remain fixed within the embolizing agent to prevent systemic escape and undesired toxic effects on the body.

Application Fields

  • Treatment of tumorigenic cancers, especially those that are highly vascularized
  • Treatment of vascular disorders such as arteriovenous malformations and cerebral aneurysms
  • Prevention or treatment of tissue bleeding and hemorrhaging


  • Preclinical studies in porcine and nonhuman primate models show 100 percent success rates in localized delivery of the technology to the renal artery.
  • The technology effectively ablates specific regions of animal kidney tissue, while the surrounding tissue remains unaltered.
  • Larger-scale animal studies will be conducted to further validate the effects of the technology on renal tissue.
  • Optimization of thermal gradients and radiofrequency power in an in vitro model will be initiated soon.
  • Patent application filed


David L. Carroll, PhD, Physics
Joel L. Berry, PhD, Biomedical Engineering
Pierre H. Rolland, PhD, Physiology

Licensing Contact

Charlie Shaw, PhD
Commercialization Associate

Back to Top